GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Abstract
Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetite- and reward-related brain areas. Obese T2DM patients and normoglycemic obese and lean individuals (n = 48) were studied in a randomized, crossover, placebo-controlled trial. Using functional MRI, we determined the acute effects of intravenous administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade using exendin 9-39, on brain responses to food pictures during a somatostatin pancreatic-pituitary clamp. Obese T2DM patients and normoglycemic obese versus lean subjects showed increased brain responses to food pictures in appetite- and reward-related brain regions (insula and amygdala). Exenatide versus placebo decreased food intake and food-related brain responses in T2DM patients and obese subjects (in insula, amygdala, putamen, and orbitofrontal cortex). These effects were largely blocked by prior GLP-1 receptor blockade using exendin 9-39. Our findings provide novel insights into the mechanisms by which GLP-1 regulates food intake and how GLP-1 receptor agonists cause weight loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 reduces appetite and food intake through its actions in the CNS.212,260,261”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“GLP-1RAs work via numerous mechanisms that contribute to weight loss, one of the most well-known of which is the gut-brain axis.212,213,390”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [212]
In the citing paper
“Incretin therapies work in the appetite and reward circuitries to modulate food intake and energy balance, reducing uncontrollable hunger, overeating, and bulimic symptoms (413), although mechanisms are not completely understood.”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [413]
Citations
Cites
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385 · cited 1×
“The global rise in obesity and type 2 diabetes (T2DM) prevalence is a major public health problem (1,2).”
BackgroundIDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 3,994
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 stimulates meal-related insulin secretion, inhibits glucagon release, and delays gastric emptying, mechanisms that all contribute to its glucometabolic effects (11).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“The weight reduction seen during GLP-1 receptor agonist treatment is also observed in the absence of nausea (47).”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“In contrast to previous studies (50), we found no statistically significant effects of GLP-1 receptor activation on scores of hunger, fullness, appetite, prospective food consumption, and desire to eat.”
ResultBaxter, M. G., & Murray, E. A. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn875 · Cited by 1,200 · cited 1×
“The amygdala plays a pivotal role in emotional learning and in the association of cues with reward (33) by encoding the value of the reward predicted by the conditioned stimuli (34).”
BackgroundChanges in brain activity related to eating chocolate: From pleasure to aversion
Small, D. M. (2001) · Brain · doi:10.1093/brain/124.9.1720 · Cited by 1,179 · cited 4×
“The insula is involved in the processing of food-cues and craving for food (31) and has been implicated in the devaluation of food-cues when eating to satiety (32).”
BackgroundInfluentialDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 3×
“A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.”
BackgroundMethodVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 6×
“Interestingly, GLP-1-receptor agonists have shown modest but consistent weight loss in humans (14).”
BackgroundResultInfluential
Research works printed but not linked: 1
- Wald, 1990, The shortened version of the Dutch translation of the Profile of Mood States (POMS), Ned Tijdschr Psychol, 45, 86
Cited by
Items 201–300 of 498
Psilopanagioti, A., Nikou, S., Logotheti, S., Arbi, M., Chartoumpekis, D. V., & Papadaki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314899 · Cited by 22
“GLP-1 and NUCB2/nesfatin-1 share similar physiologic properties in energy homeostasis and body weight [2,11,15,31].”
BackgroundPatino, L. R., Strawn, J. R., Adler, C. M., Blom, T. J., Welge, J. A., & DelBello, M. P. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.046 · Cited by 22
Özbek, L., Shah, E., Al-Shiab, R., İnal, A., Güldan, M., Afşar, B., Covic, A. C., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70699 · Cited by 22
“GLP-1RAs exert sustained effects on appetite regulation, insulin sensitivity, and body weight [46–49]; abrupt cessation before or in early pregnancy may lead to rapid weight regain, worsening insulin resistance, and compensatory hyperglycaemia, thereby increasing the risk of excess gestational…”
Novelle, M. G., & Diéguez, C. (2018) · European Eating Disorders Review · doi:10.1002/erv.2641 · Cited by 22
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Hinton, W., Feher, M. D., Munro, N. M., Walker, M., & de Lusignan, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13710 · Cited by 22
Molina‐Castro, M., Seyedsadjadi, N., Nieto, D., Leggio, L., Rowitz, B. M., & Pepino, M. Y. (2024) · Addiction Biology · doi:10.1111/adb.13441 · Cited by 21
“5 4, 6, 7 Although To better determine the potential of GLP-1-based therapies for AUD, it is also important to understand how alcohol consumption affects endogenous GLP-1 responses.”
BackgroundMaurer, L., Mai, K., Krude, H., Haynes, J., Weygandt, M., & Spranger, J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.014 · Cited by 21
Kahleová, H., Tintěra, J., Thieme, L., Veleba, J., Klementová, M., Kudláčková, M., Malínská, H., Oliyarnyk, O., Marková, I., Haluzík, M., et al. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2020.10.005 · Cited by 21
Llach, C.-D., Badulescu, S., Tabassum, A., Shah, H., Gill, H., Le, G. H., Vieta, E., McIntyre, R. S., Rosenblat, J. D., & Mansur, R. B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03261-0 · Cited by 20
“These effects likely involve not only enhanced satiety but also diminished reward valuation [175, 176], pointing to broader neuromodulatory mechanisms.”
Farr, O. M., & Mantzoros, C. S. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.231 · Cited by 20
Relationship between Parental Feeding Practices and Neural Responses to Food Cues in Adolescents
Allen, H. A., Chambers, A., Blissett, J. M., Chechlacz, M., Barrett, T. G., Higgs, S., & Nouwen, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157037 · Cited by 20
“Nucleus Accumbens, caudate, putamen) limbic (amygdala, hypothalamus, thalamus) and cortical areas such as the insula or inferior parietal cortex in response to food cues or images [64, 65].”
Khan, M. S., & Lea, J. P. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03652-5 · Cited by 19
Effects of Bariatric Surgery on Energy Homeostasis
Li, W., & Richard, D. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.05.002 · Cited by 19
Changes in Reward after Gastric Bypass: the Advantages and Disadvantages
Scholtz, S., Goldstone, A. P., & le Roux, C. W. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0534-5 · Cited by 19
Budin, A. J., Brown, W. A., MacCormick, A. D., Caterson, I. D., & Sumithran, P. (2025) · Obesity Reviews · doi:10.1111/obr.13927 · Cited by 18
A Review of the Effects of Adolescent Cannabis Use on Physical Health
Tuvel, A. L., Winiger, E. A., & Ross, J. M. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.07.005 · Cited by 18
Smith, K., Taylor, G., Allerton, D. M., Brunsgaard, L. H., Davies, K. A. B., Stevenson, E., & West, D. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.696977 · Cited by 18
“However, the physiological and hormonal changes that result in objective reductions in energy intake are not always noticeable at the subjective level (62).”
BackgroundD-allulose ameliorates adiposity through the AMPK-SIRT1-PGC-1α pathway in HFD-induced SD rats
Lee, G., Peng, C. Y., Lee, H., Park, S., Hoang, T., Kim, J., Sa, S., Kim, G., Han, J.-S., & Chae, H. (2021) · Food & Nutrition Research · doi:10.29219/fnr.v65.7803 · Cited by 18
“This demonstrated a temporary decrease in food intake and then consequently observed a recovery on the level of food intake in chronic administration (40, 41).”
BackgroundInvolvement of the Dorsal Vagal Complex in Alcohol-Related Behaviors
Keller, B. N., Hajnal, A. S., Browning, K. N., Arnold, A. C., & Silberman, Y. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.801825 · Cited by 18
Fluitman, K. S., Wijdeveld, M., Davids, M., van Ruiten, C. C., Reinders, I., Wijnhoven, H. A. H., Keijser, B. J. F., Visser, M., Nieuwdorp, M., & IJzerman, R. G. (2023) · Nutrients · doi:10.3390/nu15020332 · Cited by 18
“The fMRI picture task was performed as described previously [31].”
MethodSelf-citationCoppin, G., Tord, D. M., Pool, E. R., Locatelli, L., Achaïbou, A., Erdemli, A., Pérez, L. L., Wuensch, L., Cereghetti, D. M., Golay, A., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01370-w · Cited by 17
Jones, S., Hyde, A., & Davidson, T. L. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.05.001 · Cited by 18
Zapparoli, L., Devoto, F., Giannini, G., Zonca, S., Gallo, F., & Paulesu, E. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103179 · Cited by 17
Food reinforcement architecture: A framework for impulsive and compulsive overeating and food abuse
Burger, K. S. (2023) · Obesity · doi:10.1002/oby.23792 · Cited by 17
Perakakis, N., Farr, O. M., & Mantzoros, C. S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14315 · Cited by 17
“Previous studies by our group and others have identified GLP-1 receptors in the human brain and have shown that short-term treatment with GLP-1RAs decreases activation in the insula, putamen, caudate and orbitofrontal cortex (areas of reward system), which may lead to lower energy intake and may thus contribute to wei…”
ResultGLP1, an Important Regulator of Intestinal Lipid Metabolism
Dallinga‐Thie, G. M., & Nieuwdorp, M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305479 · Cited by 17
Conley, T. E., White, K., Bond, A., Harrison, S. J., McLaughlin, J. T., & Lal, S. (2023) · Frontline Gastroenterology · doi:10.1136/flgastro-2023-102402 · Cited by 16
Dusilová, T., Kovář, J., Laňková, I., Thieme, L., Hubáčková, M., Šedivý, P., Pajuelo, D., Burian, M., Dezortová, M., Miklánková, D., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206100 · Cited by 16
“Importantly, GLP-1 receptor agonists also exhibit central effects in reducing appetite and food intake [25], and this also explains the beneficial effect of semaglutide treatment on weight loss [26].”
BackgroundBabazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
“Digital tools like smartphone applications, photograph-assisted logs, or web-based recalls can reduce burden and improve feasibility [165].”
Koide, Y., Kato, T., Hayashi, M., Daido, H., Maruyama, T., Ishihara, T., Nishimura, K., Tsunekawa, S., & Yabe, D. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1638681 · Cited by 16
van Ruiten, C. C., Veltman, D. J., Nieuwdorp, M., & IJzerman, R. G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.863592 · Cited by 16
“05) at the voxel level using small volume correction within the predefined ROIs, using 10-mm radius spheres (5-mm sphere for the amygdala) as described previously (15, 28).”
BackgroundMethodSelf-citationSchiavo, L., Aliberti, S. M., Calabrese, P., Senatore, A. M., Severino, L., Sarno, G., Iannelli, A., & Pilone, V. (2022) · Nutrients · doi:10.3390/nu14102060 · Cited by 16
“The endocannabinoid system regulates “on demand” the production and degradation, by specific pathways, of arachidonic acid derivatives, N-arachidonoylethanolamide (anandamide, AEA) and 2-arachidonoylglycerol (2-AG), and their high-affinity cannabinoid receptors (CB) 1 and CB 2 [50].”
BackgroundJones, S., LUO, S. H., Dorton, H. M., Yunker, A. G., ANGELO, B. C., DEFENDIS, A. W., Monterosso, J. R., & Page, K. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.638504 · Cited by 16
“In humans, neuroimaging studies in humans have found that infusions of GLP-1 (11) and GLP-1 agonists (12), or glucoseinduced GLP-1 increases (13, 14) alter brain responses to food cues in regions of the brain involved in the regulation of eating.”
BackgroundPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_8 · Cited by 16
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
Zhong, J., Maiseyeu, A., & Rajagopalan, S. (2015) · Clinical Lipidology · doi:10.2217/clp.14.59 · Cited by 16
Boianelli, A., Nordell, P., Earl, J., Naylor, J., Hornigold, D. C., Jansson‐Löfmark, R., & Sundqvist, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101310 · Cited by 15
Ali, A., Khan, D., Dubey, V., Tarasov, A. I., Flatt, P. R., & Irwin, N. (2024) · Biomolecules · doi:10.3390/biom14121520 · Cited by 15
Violette, C. J., Agarwal, R., Mandelbaum, R. S., González, J. L., Hong, K. M., Roman, L. D., Klar, M., Wright, J. D., Paulson, R. J., Obermair, A., et al. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2194636 · Cited by 15
Semaglutide for Weight Loss: Was It Worth the Weight?
Novograd, J., Mullally, J., & Frishman, W. H. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000430 · Cited by 15
“Various mechanisms of weight loss have been proposed, including reduced hunger, reduced energy intake, increased satiety and direct activation of discrete sites within the hypothalamus.(19,27) In a trial investigating the mechanism of weight loss with semaglutide, data suggested that reduced energy intake was the grea…”
BackgroundKumar, N., & D’Alessio, D. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac276 · Cited by 14
Cook, G. (2026) · Cureus · doi:10.7759/cureus.100818 · Cited by 14
“Van Bloemendaal et al. (2014) conducted a pioneering human study in this area [13].”
GLP‐1 at the Metabolic–Cognitive Interface: Reward, Affect, and Memory
Gao, S., Décarie-Spain, L., Gu, C., Mazzini, G., Kanoski, S. E., & Borner, T. (2026) · Comprehensive physiology · doi:10.1002/cph4.70129 · Cited by 14
“For example, acute administration of Ex-4 reduces food intake and dampens activation in the insula, amygdala, putamen, and orbitofrontal cortex, effects that are blocked by GLP-1R antagonism (van Bloemendaal et al. 2014).”
Jensterle, M., Ferjan, S., Battelino, T., Kovač, J., Battelino, S., Šuput, D., Vovk, A., & Janež, A. (2021) · Trials · doi:10.1186/s13063-021-05442-y · Cited by 14
The future of neuroimaging and gut-brain axis research for substance use disorders
Colón-Pérez, L. M., Montesinos, J. S., & Monsivais, M. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147835 · Cited by 14
What Twin Studies Tell Us About Brain Responses to Food Cues
Schur, E. A., & Carnell, S. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0282-7 · Cited by 14
Incretins: B eyond type 2 diabetes
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 14
Yammine, L., Verrico, C. D., Versace, F., Webber, H. E., Suchting, R., Weaver, M. F., Kosten, T. R., Alibhai, H., Cinciripini, P. M., Lane, S. D., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072707 · Cited by 13
Arefin, T. M., Börchers, S., Olekanma, D. I., Cramer, S. R., Sotzen, M. R., Zhang, N., & Skibicka, K. P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110348 · Cited by 13
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
D’Annibale, D. A., Mimoto, M. S., McCowen, K. C., & Malhotra, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001208 · Cited by 13
Dumiaty, Y., Underwood, B., Phy-Lim, J., & Chee, M. J. (2024) · Neuropeptides · doi:10.1016/j.npep.2024.102427 · Cited by 9
“Exenatide reduced food intake via GLP-1R independently of other hormonal or metabolic factors (van Bloemendaal et al., 2014).”
BackgroundPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_8-1 · Cited by 13
Farokhnia, M., Sheskier, M. B., Lee, M. R., Le, A. N., Singley, E., Bouhlal, S., Ton, T., Zhao, Z., & Leggio, L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.011 · Cited by 13
“GLP-1 receptors are widely expressed in the brain regions responsible for stress and reward processing, and growing evidence underscores the role of GLP-1 in alcohol seeking and other addictive behaviors (Egecioglu et al., 2013; Suchankova et al., 2015; van Bloemendaal et al., 2014).”
Jensterle, M., Kovac, J., Vovk, A., Ferjan, S., Battelino, S., Battelino, T., & Janez, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf278 · Cited by 12
Short-chain fatty acids in clinical practice: where are we?
Martindale, R. G., Mundi, M. S., Hurt, R. T., & McClave, S. A. (2024) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001101 · Cited by 12
GLP-1 agonists: a game changer in pain treatment and addiction
Bade, S., Hurdle, M. F. B., Bade, S., Encalada, S., Kanahan-Osman, S., & Gupta, S. (2025) · Pain Management · doi:10.1080/17581869.2025.2536998 · Cited by 12
Kolnikaj, T. S., Herman, R., Janež, A., & Jensterle, M. (2022) · Life · doi:10.3390/life12111906 · Cited by 12
Alabdulkader, S., Al‐Alsheikh, A. S., Miras, A. D., & Goldstone, A. P. (2024) · NeuroImage Clinical · doi:10.1016/j.nicl.2024.103563 · Cited by 12
“…GLP-1 and PYY after RYGB surgery might mediate decreases in food hedonic responses, and a shift in food preferences away from high-energy dense foods (Batterham et al., 2007; de Silva et al., 2011; Scholtz et al., 2014; van Bloemendaal et al., 2014; Goldstone et al., 2016; Ten Kulve et al., 2017).”
BackgroundJust a Gut Feeling: Central Nervous Effects of Peripheral Gastrointestinal Hormones
Roth, C. L., & Doyle, R. P. (2017) · Endocrine development · doi:10.1159/000475734 · Cited by 12
Comfort Foods in the Twenty-First Century: Friend or Foe?
Holt, R. R., Schmitz, H. H., Mhawish, R., Komarnytsky, S., Nguyen, T. H., Caveney, P. M., & Munafo, J. P. (2024) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-111523-122109 · Cited by 11
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
Medici, B. B., Nygaard, B., la Cour, J. L., Krakauer, M., Brønden, A., Sonne, M. P., Holst, J. J., Rehfeld, J. F., Vilsbøll, T., Faber, J. O., et al. (2023) · Endocrine Connections · doi:10.1530/ec-23-0314 · Cited by 11
Omachi, T., Ohara, M., Fujikawa, T., Kohata, Y., Sugita, H., Irie, S., Terasaki, M., Mori, Y., Fukui, T., & Yamagishi, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01493-3 · Cited by 11
“GLP-1 slows down gastric emptying and suppresses appetite by promoting satiety and inhibiting hunger through the central nervous system, thereby leading to BW loss [38, 39].”
BackgroundSemaglutide and obesity: beyond the nutritional and lifestyle intervention?
Basile, L., Cannarella, R., Iuliano, S., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04103-9 · Cited by 11
Lela, L., Carlucci, V., Kioussi, C., Choi, J., Stevens, J. F., Milella, L., & Russo, D. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400559 · Cited by 11
van Duinkerken, E., Bernardes, G., van Bloemendaal, L., Veltman, D. J., Barkhof, F., Mograbi, D. C., Gerdes, V. E. A., Deacon, C. F., Holst, J. J., Drent, M. L., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14233 · Cited by 11
Self-citationBai, Y., Zhao, Y. C., Jin, J., Ye, Z., Fan, H., Zhao, D., & Gao, S. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156100 · Cited by 10
Metabolic Dysfunction in Idiopathic Intracranial Hypertension: Current Theories and Updates
Li, H., Liu, L., Zhou, Y., Jiang, H., Zhang, W., Zhou, C., Wu, C., Zhou, C. Y., & Ji, X. (2024) · Aging and Disease · doi:10.14336/ad.2024.1147 · Cited by 10
Glucagon-Like Peptide-1 Receptors in the Gustatory Cortex Influence Food Intake
Dossat, A. M., Kokoska, M. M., Whitaker‐Fornek, J. R., Sniffen, S. E., Kulkarni, A. S., Levitt, E. S., & Wesson, D. W. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1668-22.2023 · Cited by 10
Shand, J. A. D., Young, S., Verster, F., & Peters, C. N. (2023) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2023-000733 · Cited by 10
Consensus on pharmacological treatment of obesity in Latin America
Cappelletti, A. M., Montero, A. V., Cercato, C., Ossman, J. J. D., Vasquez, P. E. F., García, J. E. G., Mancillas‐Adame, L. G., Manrique, H. A., Monterroso, F. D. M. R., Segarra, P., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13683 · Cited by 10
The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery
Wang, X., Ma, H., Wang, F. Q., Long, H., Li, C., Nie, M., Han, Q., Mao, J., & Wu, X. (2025) · Clinical Endocrinology · doi:10.1111/cen.15262 · Cited by 9
Almohammad, A. A., Aldossari, S. K., Sukumbaji, Z. A., Faden, R. A., Almutairi, M. A., Al-Harbi, N. H., Al-Saaib, M. Y., Almarshedy, B., Alharabi, E., Alhazri, W. A., et al. (2025) · Cureus · doi:10.7759/cureus.95792 · Cited by 9
Qiao, H., Ren, W.-N., Li, H.-Z., & Hou, Y.-X. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.03.002 · Cited by 9
Brain-Based Etiology of Weight Regulation
Burger, K. S., Shearrer, G. E., & Sanders, A. J. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0667-5 · Cited by 9
Dagher, A., Neseliler, S., & Han, J.-E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-805308-9.00032-4 · Cited by 9
Food reward and gut-brain signalling
Thanarajah, S. E., & Tittgemeyer, M. (2020) · e-Neuroforum · doi:10.1515/nf-2019-0020 · Cited by 9
“Recent studies provide evidence for effects of gastrointestinal hormones, such as insulin and GLP1, on brain reward pathways and food intake reg- ulation following intranasal and intravenous application (Bloemendaal et al., 2014; Tiedemann et al., 2017).”
BackgroundTolerance Does Not Develop Toward Liraglutide’s Glucose-Lowering Effect
Sedman, T., Vasar, E., & Volke, V. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00199 · Cited by 9
“2 administration of exenatide has been demonstrated t o reduce food-induced brain responses [7].”
BackgroundHolt, J., Sandsdal, R. M., Byberg, S., Janus, C., Juhl, C. R., Jørgensen, J. R., Hartmann, B., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2025) · Obesity · doi:10.1002/oby.70043 · Cited by 8
“However, the effect of GLP-1 RAs depends on constantly high concentrations and sustained activation of the GLP-1 receptor in the brain to inhibit appetite [8, 9].”
Baumer-Harrison, C., Graham, M., Jonghe, B. C. D., & Hayes, M. R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.015 · Cited by 8
Central Nervous System Regulation of Eating and Brain Functions
Asuku, A. O., Ayinla, M. T., & Ajibare, A. J. (2024) · Nutritional neurosciences · doi:10.1007/978-981-97-2681-3_4 · Cited by 8
Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk
McIntyre, R. S. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.019 · Cited by 7
Obesity in Adults: Causes, Health Consequences, and Treatment Methods
Jakubiec, J., Gmitrzuk, J., Malinka, Z., Wiśniewska, K., Jachymek, A., Opatowska, M., Kucharski, T., & Karasiński, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.17.53051 · Cited by 7
“Studies have shown these medications result in significant weight loss and improvement in metabolic parameters [35].”
BackgroundLiu, J., Du, H., Song, Y., Wang, J., Tian, W., Zhong, R., Cao, Y., Xiao, H., & Wang, Q. (2025) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2025.2505240 · Cited by 7
Patel, H., Munir, K. M., Sutherland, S.-B., Karanikas, C. A., & Кониг, М. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00709-9 · Cited by 7
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Diamant, M., den Bos, I. C. P.-V., van Raalte, D. H., & Cahen, D. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12612 · Cited by 7
“This schedule was chosen because it yields exenatide plasma levels within the therapeutic range (130–150 pg/ml), has similar pharmacokinetics to subcutaneous injection, and is well tolerated [26,27].”
BackgroundSelf-citationKanu, C., Boye, K. S., Poon, J. L., GOETZ, I. A., WILLIAMSON, S. E., Lou, J., Hartman, M. L., Martin, C. K., & Coşkun, T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70097 · Cited by 6
O’Connor, R. M. (2026) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2026.1805953 · Cited by 6
Davidson, J. A., Stager, W., Paranjape, S., Berria, R., & Leiter, L. A. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0088-5 · Cited by 6
Canário, N., Crisóstomo, J., Moreno, C., Duarte, J. V., Duarte, I. C., Ribeiro, M., Caramelo, B., Gomes, L. V., Matafome, P. N., Oliveira, F. P. M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27412 · Cited by 6
“One study addressed the relationship of between GLP-1 receptor activation (using receptor agonists) and brain activity in patients with T2D sample and it was performed using a food visualization task [44].”
MethodThe Contribution of the Brain–Gut Axis to the Human Reward System
Karaivazoglou, K., Aggeletopoulou, I., & Triantos, C. K. (2024) · Biomedicines · doi:10.3390/biomedicines12081861 · Cited by 6
Knakker, B., Inkeller, J., Kovács, P., Lendvai, B., & Hernádi, I. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01981-5 · Cited by 6
“Data from animal studies further suggest that the appetite suppressant (anorectic) effects of GLP-1R agonists are also manifested through mesolimbic GLP-1R activation, that in turn alters the rewarding value of food [23 – 29].”
Exenatide modulates visual cortex responses
Binda, P., Eldor, R., Huerta, C., Adams, J. M., Lancaster, J. B., Fox, P. T., Prato, S. D., DeFronzo, R. A., Abdul‐Ghani, M. A., & Daniele, G. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3167 · Cited by 6
Impact of Gut and Metabolic Hormones on Feeding Reward
Klockars, A., Levine, A. S., Head, M. A., Perez‐Leighton, C. E., Kotz, C. M., & Olszewski, P. K. (2021) · Comprehensive physiology · doi:10.1002/cphy.c190042 · Cited by 6
Chartoumpekis, D. V., Habeos, E. E., & Psilopanagioti, A. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100104 · Cited by 6
Neural responses to food cues in middle to older aged adults: a scoping review of fMRI studies
Bennett, C., Burrows, T. L., Pursey, K., Poudel, G. R., Ng, K. W., Nguo, K., Walker, K. Z., & Porter, J. A. (2020) · Nutrition & Dietetics · doi:10.1111/1747-0080.12644 · Cited by 6
Spetter, M. S. (2018) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000493 · Cited by 6
Foscue, E. P., Trinko, R., Jiménez, J. L., Kong, E., Thompson, S. L., Stankewich, K., Corstens, A. M., Serlie, M. J. M., Taylor, J. R., & Dileone, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.08.681212 · Cited by 6
Kittah, E., Camilleri, M., Jensen, M. D., & Vella, A. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0049 · Cited by 5
Synthetic exendin-4 disrupts responding to reward predictive incentive cues in male rats
Wakabayashi, K. T., Baindur, A. N., Feja, M., Suarez, M., Chen, K., Bernosky‐Smith, K. A., & Bass, C. E. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2024.1363497 · Cited by 5
Metadata
- Authors
- van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M.
- Affiliations
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Eli Lilly (United States) (US)
- Amsterdam Neuroscience (NL)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-11-13
- Volume
- 63
- Issue
- 12
- Pages
- 4186-4196
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2018940614
- Cited by
- 427
- References
- 56
- Citations by year
- 2026: 52 · 2025: 60 · 2024: 44 · 2023: 39 · 2022: 25 · 2021: 35 · 2020: 28 · 2019: 25 · 2018: 22 · 2017: 30 · 2016: 34 · 2015: 29 · 2014: 4
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- VU Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, exenatide, exendin-9-39, appetite regulation, food reward, food images, obesity, type 2 diabetes, satiety, insula, amygdala, orbitofrontal cortex, putamen, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Adult, Aged, Amygdala, Appetite, Brain, Cerebral Cortex, Diabetes Mellitus, Type 2, Feeding Behavior, Female, Humans, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Middle Aged, Obesity, Peptide Fragments, Peptides, Photic Stimulation, Putamen, Reward, Venoms, Case-Control Studies, Prefrontal Cortex, Receptors, Glucagon, Cross-Over Studies, Functional Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.